Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

CVS Health : Expanding Access to Naloxone Saves Lives

share with twitter share with LinkedIn share with facebook
share via e-mail
06/12/2017 | 12:28pm CET

Release date- 09062017 - CVS Health - Expanding Access to Naloxone Saves Lives.

According to the Centers for Disease Control and Prevention, more than 50,000 people died from drug overdoses in the U.S. in 2015.1 More than 60 percent involved an opioid.2

We know that Americans from all walks of life are finding that prescription drug abuse is hitting closer and closer to home; nearly one in three Americans report that they have been personally affected, according to a recent survey conducted by CVS Health.

While abuse-prevention education and outreach programs are vital for curbing drug misuse and abuse, one strategy that can help communities address overdoses in the moment is ensuring access to the life-saving drug naloxone.

What is Naloxone?

Naloxone, also known by the brand name Narcan, is a lifesaving drug that blocks opioid receptor sites to reverse the effects of an overdose.3 Over the past two years CVS Health has worked to expand access to naloxone without individual prescriptions in 41 states, most recently to CVS Pharmacy patients in Arizona.

Increasing Access to Naloxone Saves Lives

Many states have recently passed Naloxone Access Laws (NALs) that widen access to naloxone by providing specific statutory protections for nonmedical professionals to possess and administer naloxone without a prescription. This enables any person without a prescription to have naloxone and to give it to a person showing signs of an opioid overdose without having to fear legal repercussions.4

According to the National Bureau of Economic Research (NBER),5 states that have adopted NALs have seen a nine to 11 percent reduction in opioid-related deaths. This research underscores the importance of increasing access to naloxone as part of a larger strategy to address the impact of prescription drug abuse.

Community Leaders Amplify Naloxone's Value

During an event hosted by CVS Health, Arizona State Attorney General Mark Brnovich and State Representative Heather Carter joined CVS Health in announcing that naloxone would be available at all Arizona CVS Pharmacy locations without a prescription. Their remarks echoed the importance of naloxone in addressing prescription drug abuse and opioid abuse more broadly.

'The opioid epidemic is an urgent public health crisis facing Arizona and the entire country,' said Attorney General Brnovich. 'We want to ensure that Arizona families who have loved ones struggling with addiction have access to naloxone because it saves lives.'

Representative Carter, a sponsor of the naloxone access legislation signed into law last year, added, 'The main purpose behind the legislation I sponsored was to get this medication in the hands of a person who may have an opportunity to save a life.'

Our Ongoing Work

Opioid abuse is an epidemic that does not discriminate, and it continues to be an area of great concern and focus for CVS Health. There is no single cause to the problem, and the solution will require a multipronged effort including pharmacy, physicians, the pharmaceutical industry and government.

In addition to expanding access to naloxone, CVS Health is working to help communities address prescription drug abuse through education, outreach and safe medication disposal:

CVS Health's Medication Disposal for Safer Communities Program has donated more than 750 collection units to law enforcement partners across the country, allowing for the safe disposal of more than 80 metric tons of unwanted medication. This program offers an online search tool through which anyone can find a drop box location near them.

Pharmacists volunteering through the company's Pharmacists Teach program have helped educate more than 250,000 students about the dangers of prescription drug abuse.

For more information about our efforts in the fight against opioid abuse, visit our Prescription Drug Abuse information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH
03/16CVS PHARMACY : Now Offering New Shingles Vaccine at Locations Nationwide
03/15CVS HEALTH : Applauds New Legislation to Better Inform Pharmacy Choices
03/14CVS HEALTH : WN grad leads at CVS
03/14DAILY DIVIDEND REPORT : Tol, irt, cvs, o, maa
03/14CVS HEALTH CORPORATION : Announces Quarterly Dividend
03/13CVS HEALTH : Health Care Shares Up as Shareholders Approve Deal -- Health Care R..
03/13CVS HEALTH CORP : Submission of Matters to a Vote of Security Holders, Other Eve..
03/13AETNA : CVS, Aetna Shareholders Back $69 Billion Deal
03/13CVS HEALTH : Stockholders Approve CVS Health's Acquisition of Aetna -- Update
03/13CVS HEALTH : Stockholders Approve Aetna Acquisition
More news
News from SeekingAlpha
08:47aSTOCKS TO WATCH : Wake-Up Call For The IPO Market 
03/16Employer Sponsored Health Insurance - The Shrinking Core And Backbone 
03/16FINDING VALUE : 5 Attractively Priced Stocks Uncovered By Our 3 Favorite Multipl.. 
03/15Value Investors Might Want To Be Careful Out There. Beware Of The Unloved Sto.. 
03/15MONTHLY REVIEW OF DIVGRO : February 2018 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 961 M
Net income 2018 5 788 M
Debt 2018 20 750 M
Yield 2018 3,26%
P/E ratio 2018 12,08
P/E ratio 2019 10,76
EV / Sales 2018 0,46x
EV / Sales 2019 0,43x
Capitalization 66 817 M
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 88,2 $
Spread / Average Target 34%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-9.45%66 817